It's not all bullish in the biotech sector. Analysts remains bearish and neutral on Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Gilead Sciences, Inc. (NASDAQ:GILD), respectively, as Valeant faces legal battles and Gilead gains new FDA dosing ...
Valeant Pharmaceuticals International, Inc. (VRX) ended last trading session with a change of 3.87 percent. It trades at an average volume of 33.95M shares versus 22.34M shares recorded at the end of last trading session.
Valeant Pharmaceuticals International Inc. is exploring the sale of some of its smaller cosmetic and pharmaceutical assets, according to people familiar with the matter, as the Canadian drugmaker scrambles to raise cash and reduce debt.
Warren Buffett, the billionaire chairman of Berkshire Hathaway Inc., faulted Valeant Pharmaceuticals International Inc.'s habit of pursuing strategies that looked good in the short term but were doomed to come to a bad end.
On Wednesday, outgoing CEO Michael Pearson and one of the largest investors, Bill Ackman, testified before the Senate in connection to Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) raising the prices of drugs, in some cases 500-1,000%.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) received severe criticism from the Securities and Exchange Commission (SEC) for its use of its adjusted “non-GAAP” financial measures and its disclosure policies.
The Company announced that, on May 11, 2016, it applied for a customary management cease trade order (“MCTO”) from the Autorit� des march�s financiers (the “AMF”), the Company's principal securities regulator in Canada, relating to the trading in ...